Dr. Dudu Tong, the R&D Director of Leman Biotech, has been actively participating in discussions and conferences related to the application of artificial intelligence (AI) in the biotech industry. As AI continues to generate significant interest and expectations, Leman Biotech's AI pipeline has achieved remarkable milestones, gaining attention in the field.
On April 20, Dr. Tong was invited to a live online conference organized by BIONNOVA, focusing on the theme of the "ChatGPT era" and the potential of AI in the field of cell and gene therapy (CGT). During the session, Dr. Tong shared the latest progress of Leman Biotech's AI superkine pipeline and engaged in discussions about the application of AI computational models in biopharmaceutical development. The discussion encompassed the efficiency of AI in preclinical drug development, its potential application scenarios in clinical trials, a comparison with traditional methods like computational chemistry, and the potential risks associated with AI in the biopharmaceutical field.
Additionally, on April 23, Dr. Tong participated in a closed-door workshop called "Think Early" organized by Cytiva and EPharma Manager. In this workshop, Dr. Tong presented the latest advancements in Leman Biotech's R&D pipeline and clinical trials to participants from biopharmaceutical companies and investment institutions. The workshop provided an opportunity for impromptu discussions and knowledge exchange.
